NEW YORK CITY, NY / ACCESS Newswire / November 5, 2026 / Cumberland Pharmaceuticals (NASDAQ:CPIX) shareholders lost almost 48.8% of their investment on October 26, 2026, after the Company reported that its Phase 2a
Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cumberland Pharmaceuticals Inc. ("Cumberland"
NASHVILLE, Tenn., Nov. 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that
NASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for
Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-driven biopharmaceutical company advancing
NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs,
NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs,
$100 million Strategic Transaction Closed Special Shareholder Dividend FundedAdvancing Late Stage Clinical Pipeline NASHVILLE, Tenn., Aug. 4, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an
NASHVILLE, Tenn., July 28, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that
/C O R R E C T I O N – Cumberland Pharmaceuticals Inc./ In the news release, CUMBERLAND PHARMACEUTICALS ANNOUNCES SPECIAL DIVIDEND OF $1.50 PER SHARE, issued July 13, 2026 by Cumberland Pharmaceuticals Inc. over PR
Record Date is July 10, 2026 & Payment Date is July 31,2026Corporate and Insider Share Purchase Initiatives to ContinueNASHVILLE, Tenn., July 13, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX),
$100 million Transaction Follows Cumberland Shareholder ApprovalStrengthens Cumberland's Focus on Rare Disease PipelineNASHVILLE, Tenn., July 1, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a
Additional cardiac biomarker analyses further demonstrate ifetroban's cardioprotective effect in DMD patientsNASHVILLE, Tenn., June 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), an
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrantsTEL AVIV, Israel and RALEIGH, N.C., June 22, 2026 /PRNewswire/ -- RedHill Biopharma
$6 million upfront with up to approximately $13.4 million of potential aggregate gross proceeds upon the exercise in full of warrantsTEL AVIV, Israel & RALEIGH, N.C., June 18, 2026 /PRNewswire/ -- RedHill Biopharma
